In this large study of high-risk EC samples from hysterectomy specimens of patients included in the PORTEC-3 trial, we corroborate the abnormal p53 IHC patterns previously described in ovarian cancer and endometrial cancer biopsy samples7,8. This evidence concerns the gene TP53 and ovarian cancer.